Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday? [Yahoo! Finance]
Deciphera Pharmaceuticals, Inc. (DCPH)
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
deciphera.com/investor-relations
Company Research
Source: Yahoo! Finance
Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. In addition to QINLOCK – Deciphera's switch-control inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST), which is approved in the U.S. and over 40 other countries, Deciphera also brings a pipeline of cancer drugs such as vimseltinib, DCC-3116 (a ULK inhibitor) and multiple additional oncology candidates. Related: Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer The purchase price represents a premium of 74.7% to Deciphera's closing share price of $14.65 on April 26, 2024, and a premium of 68.8% to Deciphera's 30-trading-day volume weighted average price as of April 26, 2024. The Acquisition is expected to close in the third quarter of 2024. Upon completion of the Acquisition,
Show less
Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCPH alerts
High impacting Deciphera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
DCPH
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, HCP, DCPHPR Newswire
- Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates Fri, May 10, 2024, 2:50 PM GMT+2 3 min read 0 In this article: Advertisement Up next Analyst adjusts Nvidia stock price target ahead of earnings Fri, May 10, 2024, 1:03 AM GMAcquire Media Monitor
- Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER ALERT: Weiss Law Investigates Deciphera Pharmaceuticals, Inc.Accesswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, DPSI, UNITGlobeNewswire
DCPH
Earnings
- 5/10/24 - Beat
DCPH
Sec Filings
- 5/13/24 - Form SC
- 5/13/24 - Form SC
- 5/10/24 - Form 10-Q
- DCPH's page on the SEC website